CCR5 and Familial prostate cancer: Most promising is CCR5 blocking by synthetic drug maraviroc, an allosteric inverse CCR5 agonist [56], which has been proven to significantly inhibit proliferation, colony formation, and migration of several carcinomas, including breast [42] and prostate cancer [55].